Lv1
40 积分 2025-10-22 加入
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
1天前
求助中
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)
11天前
已完结
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
12天前
已完结
Utility of multi-parametric quantitative magnetic resonance imaging of the lacrimal gland for diagnosing and staging Graves’ ophthalmopathy
22天前
已完结
Application of Quantitative MRI in Thyroid Eye Disease: Imaging Techniques and Clinical Practices
22天前
已完结
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
1个月前
已完结
Pharmacokinetics and Pharmacodynamic of Alpelisib
1个月前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
1个月前
已完结
A Phase I Trial of Alpelisib Combined with Capecitabine in Patients with HER2-negative Metastatic Breast Cancer
1个月前
已完结
皖公网安备34019202002308
